
Germany is rearming, but what about its veterans?
Getting to this point has taken years, though. "We've been campaigning for this Veterans' Day for nearly 15 years," said Andreas Eggert, Secretary General of the German Veterans' Association, Bund Deutscher EinsatzVeteranen e.V, speaking to Euronews.
Germany needed a day that properly acknowledges the service of its veterans. But before that could happen, the association had to reintroduce and redefine the very concept of a veteran. The word itself was long burdened by its associations with the Second World War, added David Hallbauer, the association's Deputy Federal Chairman.
The goal, he explains, was to establish a new understanding – that the Bundeswehr had developed its own, modern tradition, from which a distinct veteran identity could emerge.
When the Association of German Veterans was founded in 2010, it faced significant opposition. "People dismissed us as outdated," Hallbauer recalled. "We first had to explain that we were talking about individuals who had rendered a special service to Germany through their time in the Bundeswehr."
For the Association of German Veterans, it's not just about recognition and appreciation, but also about supporting those who were injured in service.
A National Veterans' Day can serve as a platform to highlight these issues and shine a light on the shortcomings that still need to be addressed.
This includes mental health support, particularly for soldiers suffering from post-traumatic stress disorder (PTSD). Many wait years for help. According to Eggert, the longest known case he's aware of took 13 years before support was granted.
"We have a real problem with bureaucracy dragging everything out," Hallbauer explained, adding that for those affected, it feels like a war after the war.
"These delays could be avoided by speeding up the decision-making process. If someone has to wait twelve years to be recognised, that's clearly not in anyone's interest," he said.
Before a case is approved, authorities must establish a direct link between a deployment and the resulting illness. "You first have to prove that you were even deployed," Hallbauer explained. "As someone who's been injured, you're expected to demonstrate that you were on the ground – and that the experience you had there damaged your health."
Eggert adds that in Germany, there's an additional hurdle: the traumatic event itself must meet strict criteria before any therapy or treatment is approved.
As part of what's known as the military service compensation process, the extent of an individual's injury is assessed – which then determines any potential pension entitlements.
"The process often seems designed more to fend off claims than to support those affected," said Eggert. "That's why all cases are treated in the same rigid manner at first." Personal history, including childhood experiences, is also taken into account – something the Veterans' Association sees as misguided. "Instead of focusing on individual background factors unrelated to trauma, the process should centre on the incident that occurred during deployment and the resulting physical or psychological strain," Eggert concluded.
According to him, a shift in the burden of proof would mark real progress. "It shouldn't be up to the injured person to prove that deployment made them ill, the Bundeswehr should have to prove that it didn't. That kind of reversal is exactly what's been missing so far. It appears there's no political will to change that", he told Euronews.
"It should be possible for a soldier to go on deployment with peace of mind, knowing that if they're injured, they'll be properly looked after," Hallbauer.
This sense of security, he continued, simply doesn't exist in Germany today.
Since Russia's full-scale invasion of Ukraine, defence has returned to the political agendaacross much of Europe.
Former Chancellor Olaf Scholz (SPD) declared a "Zeitenwende" – a turning point, after Russia started its full-scale invasion of Ukraine in February 2022. Defence spending has since increased, with the stated aim of making Germany "fit for war" once again.
But if a country is to be made fit for defence, the initial focus is naturally on rearmament, said Eggert. "We're facing shortages in both equipment and personnel. That's where a large portion of the money is going. But it would have been good if even just 10 million of the 100-billion-euro special fund had been set aside to properly care for those who are injured, wounded, or fall ill during deployment."
Thousands of pride parade attendees took to the streets in Vienna, Warsaw, Rome and Athens on Saturday, waving rainbow flags and holding up signs of protest as they celebrated pride month, while also demanding political and social equality for the LGBTQ+ community in their respective countries.
Warsaw's pride parade went through the city centre and headed through the Old Town. The "Equality Parade" began on Saturday afternoon, and was attended by thousands of demonstrators.
Under the slogan "Love is the answer", the event's organisers expressed the hope that they could help others to express their LGBTQ+ identity openly and without fear.
"We don't want to talk about such matters somewhere underground, we don't want to hide in basements - we come to the surface to talk about it," said Rafał Dembe, president of the Equality Volunteering Foundation at a press conference ahead of the march.
During the conference, the organisers said that the demonstration in Warsaw is the largest of its kind in the country.
Among the most notable attendees of the parade were mayor of Warsaw Rafał Trzaskowski, who recently found himself on the losing side of the country's presidential election, member of the European Parliament Robert Biedroń and Minister of Equality Katarzyna Kotula.
Four days earlier, Kotula submitted a bill to parliament to introduce civil partnerships, including for same-sex couples.
Speaking to the crowd at the start of the parade, Trzaskowski said "Remember that I have been saying for many years that together we are building Warsaw, which is an open and tolerant city, where these values are not only appreciated but also promoted."
Braving the scorching hot 35 degree weather, thousands of people walked the city of Rome from Piazza della Repubblica to Via Cavour to participate in the Italian capital's pride march. Three motorcyclists with roaring engines kicked off the parade. Right behind them was the leader of the parade, holding a large banner with the word "Outlaw", written on it. The banner is in protest of what organisers see as the conservative incumbent government's lack of support for LGBTQ+ rights.
Among those taking part in the demonstration were the spokesperson of the Capitoline parade, Mario Colamarino, and the mayor of Rome, Roberto Gualtieri.
''We are here for the rights of all, to have a more inclusive and equal Italy, better than the one we have now. 'Outlaws' is what we are in this country today, we must fight and we must be many," said Colamarino.
The event in Rome was held not only to celebrate LGBTQ+ pride, but also to protest the ongoing conflict in Gaza, for which a one-minute silence was held. Many Palestinian flags and banners were waved alongside rainbow flags, as people chanted slogans for free love and equality. Along with house and pop music, the Italian partisan anthem "Bella Ciao" was also sung by the demonstrators.
A float satirically depicting Hungarian Prime Miniser Viktor Orban - whose government was last week denied a request to hold a pride march in Budapest - was also rolled out, an initiative by the Italian +Europa party.
"Today, more than ever, it is important to attend pride at a time when in the world there are autocracies, illiberal democracies, fundamentalist regimes that attack civil rights and individual freedoms in Hungary, as well as in Russia and Trump's United States, where some words, such as 'gay', are banned on institutional websites", said the party's secretary, Riccardo Magi.
2025 marks the 20th year since the first Athens Pride was held, and this year's slogan is "We Count". This has a double meaning in Greek - the phrase can either mean "we matter", but can also mean to take stock of something. The latter is in reference to recollecting everything that has happened since June 2005, when the first Athens pride parade was held.
According to the organisers, this includes joy, such as the pride and liberation of the first years, losses due to hate and homophobic attacks, victories such as same-sex civic union and marriage, but also disappointment such as the stigma that remains, as well as the fight for visibility and rights.
"Now, more than ever, the global context shows us that no acquis (law) can be taken for granted. Instead, our rights and our very existence are being challenged every day. The rise of the far right and the normalisation of hate speech in political and media discourse are a threat to all of us. The exclusion of LGBTQ+ refugees and migrants is intensifying, leading to the exclusion of people on the basis of racist, sexist, homophobic and/or transphobic motives," the organisers say on their website.
"For all this, our presence in the public space will continue to be our undeniable right, a historical duty and an act of resistance against a public discourse of abuse that seeks to erase us. The struggle for equality is ongoing and remains unabated. We are and will be here to keep them going," the organisers say on their website.
Pride month is celebrated in Athens with a variety of cultural events, screenings, performances, parties, shows, panel discussions, workshops and seminars, many of point to the now 20-year history of pride in the Greek capital, with diversity, equity and inclusion initiatives also taking centre stage.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Euronews
2 days ago
- Euronews
Germany to allow some depressed patients to try psychedelics
Germany's medicine regulator will allow certain patients with treatment-resistant depression to try psilocybin therapy, a major shift as psychedelics inch closer to mainstream medicine. It is the first time in the European Union that psilocybin – the hallucinogenic compound in magic mushrooms – will be made available through a compassionate use scheme, in which patients with serious or life-threatening illnesses can get access to drugs that have not yet been approved. In Germany, psilocybin will only be prescribed in 'justified exceptional cases,' according to the Central Institute of Mental Health (CIMH), which asked regulators to greenlight the programme. 'This is an enormously important step that expands our scope for action,' Dr Gerhard Gründer, head of CIMH's molecular neuroimaging department, said in a statement. In some cases, psilocybin therapy 'can be a medically and ethically justifiable option, provided it is carried out under strictly controlled conditions and with careful medical supervision,' Gründer added. Depression is a common mental health problem, but approximately 20 per cent to 30 per cent of people with depression do not respond well to standard treatments, CIMH said. Studies have shown that psilocybin could be a promising alternative for these patients. The drug is thought to foster connections between different regions of the brain, helping people let go of excessive self-focus and rumination, according to scientists from the United Kingdom and United States. But sceptics have warned that studies on psychedelic drugs can be hard to replicate. Growing interest in psychedelics The decision from Germany's Federal Institute for Drugs and Medical Devices (BfArM) reflects growing interest in psychedelic therapies, including psilocybin and MDMA, as a treatment for mental health issues such as depression, anxiety, addiction, and post-traumatic stress disorder (PTSD). Earlier this month, the Czech Republic legalised the medical use of psilocybin for conditions such as depression. Meanwhile, the first EU-funded trial on psychedelic medicines launched last year to test whether psilocybin can alleviate anxiety and depression among patients with progressive diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). Other clinical trials are also underway in Europe, including in Germany, though full approval for psilocybin is not expected in Germany for several years. In the meantime, the Psychedelic Access And Research European Alliance (PAREA), a nonprofit advocacy group, said compassionate use programmes can complement clinical trials by offering real-world data on these treatments and ensuring they are available for 'patients who cannot wait' for full approval. CIMH expects that many patients will be interested in Germany's limited access scheme. 'Experience from Switzerland shows that demand far exceeds the available supply,' Gründer said. 'We must therefore continue to work on bringing psychedelics such as psilocybin into standard care for the treatment of mental illness,' he added.


Euronews
16-07-2025
- Euronews
Trump officials are pushing psychedelic therapy. Will it help or hurt?
For decades, proponents of psychedelic drugs have pushed a provocative message: Illegal, mind-altering substances like LSD and ecstasy should be approved for patients grappling with depression, trauma and other hard-to-treat conditions. In the United States, a presidential administration finally seems to agree. 'This line of therapeutics has tremendous advantage if given in a clinical setting and we are working very hard to make sure that happens within 12 months,' US health secretary Robert F Kennedy Jr recently told members of Congress. His suggested timeline for green-lighting psychedelic therapy surprised even the most bullish supporters of the drugs. The Trump administration's embrace of psychedelics has sparked both excitement as well as concern from those in the field, who worry the drugs might be discredited if they appear to be rushed onto the market or are too closely linked with Kennedy, who is known for controversial views on vaccines, antidepressants, and fluoride. 'I'm quite optimistic,' says Rick Doblin, whose organisation has pursed the medical use of MDMA (or ecstasy) since the 1980s. 'But I'm also worried that the message the public might get is 'Well, RFK likes psychedelics and now it's approved'". US regulators may reconsider MDMA Under former US President Joe Biden, the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD), citing flawed data and questionable research. Regulators called for a new study, likely taking several years. It was a major setback for Doblin and other advocates hoping to see the first US approval of a psychedelic for medical use, and European researchers said it likely set the field back there as well. But the agency appears ready to reconsider. FDA chief Marty Makary, who reports to Kennedy, has called the evaluation of MDMA and other psychedelics 'a top priority,' announcing a slate of initiatives that could be used to accelerate their approval. One new programme promises to expedite drugs that serve 'the health interests of Americans,' by slashing their review time from six months or more to as little as one month. Makary has also suggested greater flexibility on requirements for certain drugs, potentially waiving rigorous controlled studies that compare patients to a placebo group. That approach, considered essential for high-quality research, has long been a stumbling point for psychedelic studies, in which patients can almost always correctly guess whether they've received the drug or a dummy pill. Links to psychedelic advocates US health agencies also recently hired several new staffers with ties to the psychedelic movement. 'These are all very promising signs that the administration is aware of the potential of psychedelics and is trying to make overtures that they're ready to approve them,' said Greg Ferenstein, a fellow at the libertarian Reason Foundation, who also consults for psychedelic companies. As a presidential candidate, Kennedy discussed how his son and several close friends benefited from using psychedelics to deal with grief and other issues. But some experts worry the hope and hype surrounding psychedelics has gotten ahead of the science. Philip Corlett, a psychiatric researcher at Yale University, says bypassing rigorous clinical trials could set back the field and jeopardise patients. "If RFK and the new administration are serious about this work, there are things they could do to shepherd it into reality by meeting the benchmarks of medical science," Corlett said. 'I just don't think that's going to happen.' Nora Volkow, the longtime director of the US National Institute on Drug Abuse, said her agency remains interested in psychedelics. It is funding a US drugmaker that's working to develop a safer, synthetic version of ibogaine, which is a potent psychedelic made from a shrub that's native to West Africa. Texas recently launched a $50 million (€42.7 million) trial to test ibogaine as a treatment for opioid addiction, PTSD, and other conditions. 'I am very intrigued by their pharmacological properties and how they are influencing the brain,' Volkow said. 'But you also have to be very mindful not to fall into the hype and to be objective and rigorous in evaluating them".


Local France
11-07-2025
- Local France
France's death rate at ‘historically low' level
Newly published figures reveal that 637,082 residents of France died in 2023, down 36,000 on the previous year, and setting a mortality rate of 828.3 deaths per 100,000 inhabitants, a figure down 60 on 2022. The immediate downward trend is largely due to the drop in mortality caused by COVID-19 – accounting for 60 percent of the decrease, according to a joint study by the Direction de la recherche, des études, de l'évaluation et des statistiques (DREES), the Centre d'épidémiologie des causes médicales de décès de l'Inserm (CépiDc-Inserm) and Santé publique France. However the numbers also reflect a general trend of falling death rates that was seen in the pre-pandemic period. Advertisement The report, out a day after another study revealed that fewer babies were born in 2024 than in any year since the Second World War, raises questions about the future of France's social care system. READ ALSO Why French women want fewer babies 'Smaller declines are also observed for most of the major causes [of death],' the report said, which notes two exceptions: mortality from respiratory diseases and mortality from infectious and parasitic diseases, which are slightly on the rise. Despite much lower death rates than in the 2020-2022 period, Covid remained the ninth most common cause of death in 2023. Anne Fouillet, from Santé Publique France, told French newspaper Libération : "Covid mortality has followed the decline in circulation of the epidemic, which has been associated with immunisation of the population - thanks in particular to vaccination. "But it still caused 14,000 deaths in 2023, mostly among the elderly - 63 percent of the dead were aged 85 or over." The leading causes of death for both men and women remains cancer which account for more than 27 percent of deaths in France. Cancer affects a younger population on average than other causes of mortality – and are the leading cause of death among children aged one to 14, after external causes such as accidents or road traffic collisions. However, according to the report, cancer deaths are declining, 'with the exception of pancreatic cancer, which is on the rise, and lung, bronchial, and tracheal cancer in women.' Cardiovascular and cerebrovascular diseases – heart attack, stroke, heart failure – are the second leading cause of death, accounting for 21.4 percent of deaths, down slightly on figures from 2022. Advertisement These are followed, in order, by 'ill-defined symptoms and conditions,' external causes of morbidity (eg car accidents) diseases of the respiratory system (including Covid), diseases of the nervous system and sensory organs, and diseases of the digestive system. Although it is still hard to precisely disentangle the effects of the pandemic on deaths, the report's authors say that overall the deaths rates remain slightly higher than suggested by the continuation of pre-Covid trends. More than half of all deaths in France (53 percent) occur in healthcare facilities (public or private) and almost a quarter at home (24 percent). Nearly 30 percent of deaths at home involve people receiving home hospital care, up from 2022. French life expectancy currently sits at 85.3 years for females and 79.4 years for males. France also does well for the expected years of 'healthy life' - women on average in France can expect to live until the age of 64.5 years without suffering any debilitating health problem, while the average age for men living a healthy life is 63.4 years. READ ALSO : Why do the French live so long?✎